Scutellariae radix (SR, from the roots of Scutellaria baicalensis Georgi) is thought to regulate blood pressure. In this study, HPLC-based purification coupled with MS, NMR analysis revealed that baicalin, a major flavone in SR, stimulates endothelial NO generation, suggesting its potential as an ingredient in medicinal food and beverage to treat hypertension.
Scutellariae radix (SR) is a popular medicinal herb obtained from the roots of Scutellaria baicalensis Georgi, one that has been used in Asian countries in the treatment of several diseases, including cardiovascular diseases.
1) It contains flavones such as baicalin, baicalein, wogonin, and wogonoside, of which baicalin and baicalein are the most abundant.
2) Ex-vivo analyses using isolated animal organs have suggested multitudes of biological effects of SR and these flavones on blood pressure regulation. Briefly, wogonin induced relaxation of the rat aorta, while SR and baicalin caused contraction 3) or inhibited relaxation. 4) Baicalin appeared to inhibit nitric oxide (NO) production, one of the main pathways relaxing blood vessels, leading to contraction of arteries. 5) In contrast, Kim et al. found that SR stimulated NO generation in interferon-gamma treated mouse peritoneal macrophages. 6) Careful evaluation with respect to NO generation should provide important information in applying these flavones as ingredients to lower blood pressure, leading us to analyze their direct effects on vascular endothelial cells.
Twenty g of dried SR from Harbin Pharmaceutical Group (Harbin, China) was extracted with 250 mL of hexane or water by refluxing for 2 h. The hexane extract was evaporated under vacuum to dryness at room temperature, while the water extract was centrifuged at 3;000 Â g for 15 min and the supernatant was freezedried. From 20 g of starting material, we obtained 0.2 g and 7.4 g of hexane and water extract, respectively. Vascular endothelial cells were treated with these extracts, followed by analysis of NO generation. Briefly, human umbilical vein endothelial cells (HUVECs), purchased from the Health Science Research Resources Bank (Tokyo) were cultured in endothelial basal medium (EBM-2; Clonetics, Walkersville, MD) and used for analysis after 4-6 passages. The cells were treated with various concentrations of sample extracts for 24 h, and then incubated for 24 h with fluorescent probe diaminorhodamine-4M (Sekisui Medical, Tokyo). Test samples, dissolved in dimethyl sulfoxide (DMSO), were added to the culture medium so that the DMSO concentration did not exceed 1%. The cells were also treated with a specific NO scavenger, 2-phenyl-4,4,5,5-tetramethylimidazoline-3-oxide-1-oxyl (Tokyo Chemical Industry, Tokyo), to confirm NO generation. The relative ratio of NO generation was calculated from the fluorescence intensity using 560 nm for excitation and 575 nm for emission on a Hitachi F-2500 fluorescence spectrophotometer. The water extract but not the hexane extract enhanced NO generation in HUVECs in a dosedependent manner, suggesting that the SR constituents stimulating endothelial NO are hydrophilic (data not shown). The water extract that stimulated NO generation was separated by hydrophobic interaction chromatography using an Inertsil ODS-3 column (250 mm Â 4.6 mm, 5 mm, GL Sciences, Tokyo). Elution was carried out at ambient temperature with a flow rate at 1.0 mL/min. A mixture (9:1) of 2.5% aqueous acetic acid (mobile phase A) and 2.5% acetic acid-containing methanol (mobile phase B) was used as the initial mobile phase, and the ratio of mobile phase B to mobile phase A increased to 90% in a linear manner for 40 min during separation. Eluents were monitored at 280 nm with an UV detector. Detected components were separated into six fractions as shown in Fig. 1 . Although the doses of individual fractions differed, the total dose was equivalent to 1,000 mg/mL of the water extract (data not shown). The fractions were evaluated for their effects on NO generation in HUVECs by fluorescent probe. The results showed that the stimulatory activities of fractions 1, 2, 3, 4, 5, and 6 were 1:1 AE 0:06, 1:3 AE 0:08, 1:8 AE 0:08, 0:9 AE 0:05, 1:1 AE 0:01, and 1:0 AE 0:04 respectively. Among the fractions tested, Fr. 3 significantly induced endothelial NO generation, which was almost equivalent to the activity of the total water extract at 1,000 mg/mL (which showed 1:9 AE 0:12 as fluorescence intensity). This fraction was then further separated into Fr. 3-1 and Fr. 3-2, of which the latter exclusively contained a certain compound (designated component P1) and had the highest NO-generating activity. Isolated component P1 was studied to identify its structure by HPLC-MS and 1 H and 13 C-NMR The ratio of mobile phase B to mobile phase A increased linearly from 5% to 40% during the first 8 min, and then increased to 100% in the next 4 min. The capillary and cone voltages were 3 kV and 20 V respectively. The ion source temperature was maintained at 150 C. In HPLC selected reaction monitoring (HPLC-SRM) analysis, a specific daughter ion (m=z 269) was selected, and argon was used as the collision gas at 15 V collision energy.
1 H and 13 C-NMR measurement was done on a JEOL ECS 400 NMR spectrometer operating at 400 MHz for the 1 H-NMR spectra and at 100 MHz for the 13 C-NMR spectra. Chemical shifts were recorded at room temperature in pyridine-d 5 as ppm relative to the solvent signals ( 1 H-NMR, 8.71 ppm, and 13 C-NMR, 149.2 ppm). HPLC-MS analysis of component P1 gave abundant ions at m=z 445.2 and a prominent fragment ion at m=z 269.1. The former ion peak corresponded to a ½M À H À ion of the parent compound, and the latter to a fragmented ion arising from the glucuronic acid moiety of the parent molecule. These mass spectral features were identical to those of pure baicalin. In addition, component P1 was analyzed in SRM mode, in which the SRM chromatogram, produced by monitoring the daughter ion (m=z 269) derived from the parent ion (m=z 445), showed only one peak, with the same retention time as that of authentic baicalin. As for the NMR analytical data for component P1, the 163.4 (s), 171.7 (s) , and 182.7 (s). These NMR spectral features are identical to published data, 7) and to those of the pure baicalin specimen. These results strongly suggest that the stimulatory component P1 was baicalin. The endothelial NO-generating activity of baicalin was compared with that of three other flavones, baicalein, wogonin, and wogonoside, which were detected in the water extract with similar retention times in the HPLC profile (data not shown). As shown in Table 1 , only baicalin induced NO generation in the HUVECs, in dose-dependent manner. To our knowledge, these results show for the first time that baicalin stimulates endothelial NO generation. Finally, we examined whether baicalin upregulates endothelial nitric oxide synthase (eNOS) in HUVECs. Cells were treated with baicalin for 24 h. Other cells were treated with bradykinin, a peptide known to induce NOS, 8) as positive control. Then protein extracts were prepared and analyzed by Western blotting using a specific antibody toward eNOS (ab3342, Abcam, Cambridge, MA). As shown in Fig. 2 , baicalin induced the expression of eNOS in the HUVECs in dose-dependent manner, suggesting the activation of signaling pathways leading to eNOS expression.
Vasorelaxation is a major mechanism through which hypertension is relieved, and endogenous NO is known to be a strong vasodilating factor produced by vascular endothelial cells.
9) It is unclear whether SR or its major flavonoids can directly stimulate vascular endothelial cells to generate NO, despite its in vivo effect lowering blood pressure (BP). Our data clearly indicate that SR stimulates endogenous NO production in HUVECs. Subsequent investigation identified the major flavone glucuronide baicalin as the principle active component, one that directly targets the molecules involved in endothelial NO generation. These data suggest that baicalin has a function as an important regulator of BP in humans. This is also supported by the fact that baicalin is hydrolyzed to baicalein by intestinal bacteria, and that baicalein absorbed from the intestinal tract is then restored to baicalin in the blood. 10) Further studies to establish guidelines for the safe and effective use of SR as an ingredient in medicinal food and beverages and/or clinical treatment of hypertension are required to identify susceptible cell types and molecular targets, and to establish endothelial cell-specific delivery of baicalin in the treatment of hypertension.
